Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021)
Humacyte (HUMA) posted quarterly Preferred Stock Liabilities of $421.0 million for Q2 2021, little changed quarter-over-quarter from $421.0 million in Q1 2021.
Humacyte (HUMA) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Humacyte (HUMA) has reported Preferred Stock Liabilities for 2 consecutive years, with $421.0 million the latest figure, recorded in Q2 2021.
- In Q2 2021, Preferred Stock Liabilities changed N/A year-over-year to $421.0 million; the TTM figure through Jun 2021 stood at $421.0 million (changed N/A YoY), while the FY2020 annual figure was $421.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $421.0 million in Q2 2021 per HUMA's latest filing, from $421.0 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $421.0 million in Q3 2020 and bottomed at $421.0 million in Q3 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | - |
| 10 | Humacyte | 151.73 Mn | 151.73 Mn | -825,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 420.99 Mn |
| Mar 31, 2021 | 420.99 Mn |
| Dec 31, 2020 | 420.99 Mn |
| Sep 30, 2020 | 420.99 Mn |